[A21-65] Obinutuzumab (follicular lymphoma, after rituximab) - Benefit assessment according to §35a Social Code Book V

Last updated 16.08.2021

Project no.:
A21-65

Commission:
Commission awarded on 12.05.2021 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Adults with follicular lymphoma who did not respond to treatment with rituximab alone or in combination with other drugs, or whose disease has progressed during or up to 6 months after treatment with rituximab

Result of dossier assessment:

Added benefit not proven.

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.